ERNA — Ernexa Therapeutics Inc · catalysts, narrative & risks

Ernexa Therapeutics Inc. (NASDAQ: ERNA) — Research Snapshot (as of 2026-10-26)

Company / asset profile. Ernexa Therapeutics is a Cambridge, Massachusetts-based, preclinical-stage biotech developing allogeneic, "off-the-shelf" cell therapies built on an induced pluripotent stem cell (iPSC)-to-induced mesenchymal stem cell (iMSC) platform, using patented mRNA cell engineering technology [15], [18]. The company was formerly known as Eterna Therapeutics [15]. Its lead oncology program, ERNA-101, is an IL-7/IL-15 (fusokine)-secreting iMSC engineered for ovarian cancer [2], [15]. ERNA-201 is an anti-inflammatory (IL-10) secreting iMSC program for rheumatoid arthritis/inflammatory disease [15].

Recent Catalysts (last ~1–3 months)